Tesamorelin is a synthetic analogue of Growth Hormone–Releasing Hormone (GHRH), engineered to enhance stability and receptor activation at the pituitary GHRH receptor. It stimulates pulsatile GH release and downstream IGF-1 activity, making it a core research molecule for modelling GH-axis function, visceral adipose dynamics, and metabolic pathways in controlled laboratory settings.
Mechanism of Action
Tesamorelin binds to the GHRH receptor in the anterior pituitary, increasing the amplitude and frequency of natural GH pulses. This elevates systemic IGF-1 levels and influences lipolytic, metabolic, and tissue-signaling pathways.
Key Themes
- Investigated for reductions in visceral adipose tissue (VAT) in abdominal adiposity models.
- Explored for modulation of liver-fat markers and metabolic regulation.
- Assessed for effects on muscle-area and muscle-density parameters.
- Used to model GH/IGF-1 endocrine dynamics and body-composition signaling.
⚗️ Composition
- Active ingredient: Tesamorelin
- Total content: 24 mg per pen
- Total volume: 3 mL
- Form: Sterile peptide solution
- Presentation: Disposable subcutaneous injection pen
💉 Route of Administration
- Subcutaneous (SC) injection
📊 Typical Administration Protocol
Under practitioner supervision, a commonly used protocol may include:
- Dose: 0.08 mg per administration
- Pen clicks: 12 clicks
- Frequency: Once daily
Cycle Structure
- 6 consecutive days on
- 1 day off
Dosage and duration should always be determined by the supervising healthcare professional.
🧊 Storage Instructions
- Store refrigerated at 2–8 °C
- Protect from light
- Do not freeze
- Do not use if solution appears cloudy or contains visible particles
⚠️ Important Information
- For use by licensed healthcare professionals or under medical supervision
- Not intended for self-diagnosis or unsupervised self-treatment
- Single-patient use device
- Always follow the prescribing practitioner’s instructions
Reviews
There are no reviews yet.